Concepedia

Hao Zhao

HZ

Statistics

Publications

6

Citations

123

H-Index

6

Active since

2004

Affiliations

National University of Singapore(Current)

The University of Texas MD Anderson Cancer Center

Hao Zhao is an author at National University of Singapore specializing in checkpoint inhibitor therapy, immunotherapy, and immune checkpoint inhibitor therapy.

ORCID

Publications per year

2004–2025

6

Publications

6

Enhancing single-cell encapsulation in droplet microfluidics with fine-tunable on-chip sample enrichment

Tao Tang, Hao Zhao, Shaofei Shen et al. · Microsystems & Nanoengineering · 2024 · 50 citations · Full text

, , +14

The current fluctuations and accumulated pitting damage of mild steel in NaNO2–NaCl solution

Yuming Tang, Yu Zuo, Hao Zhao · Applied Surface Science · 2004 · 22 citations

, , +13

Insights into the mechanobiology of cancer metastasis via microfluidic technologies

Lanfeng Liang, Xiao Song, Hao Zhao et al. · APL Bioengineering · 2024 · 16 citations · Full text

, , +17

A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).

Jianjun Gao, José A. Karam, Nizar M. Tannir et al. · Journal of Clinical Oncology · 2018 · 13 citations

, , +16

A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).

Jianjun Gao, José A. Karam, Nizar M. Tannir et al. · Journal of Clinical Oncology · 2019 · 12 citations

, , +9

1–5 of 6